Cite
HARVARD Citation
Wu, W. et al. (2019). Butyrolactone‐I, an efficient α‐glucosidase inhibitor, improves type 2 diabetes with potent TNF‐α–lowering properties through modulating gut microbiota in db/db mice. FASEB journal. 33 (11), pp. 12616-12629. [Online].